Cancer trials often involve new treatments that have not been extensively tested in humans. The role of the DSMB is to ensure that the trial is conducted ethically and that participant safety is prioritized. They make recommendations on whether to continue, modify, or stop a trial based on interim results. This helps in early identification of any adverse effects or unexpected outcomes, ensuring that participants are not exposed to undue risk.
